Synthesized peptides, such as Romosozumab and CK2.3, promote osteoblastogenesis and limit osteoclastogenesis, making them possible therapeutics for osteoporosis by BMP-signaling without exogenous BMP-2 (Figure 4). Here, BMP2 is linked to osteoporosis.